Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

(1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON NOVEMBER 13, 2026; (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEE

According to the circular (the "**Circular**") and the notice (the "**Notice**") both dated October 28, 2026 of extraordinary general meeting (the "**EGM**") of Qyuns Therapeutics Co., Ltd. (the "**Company**"), the EGM of the Company was held at Room 1809, Tower A, The Place, No.100 Zunyi Rd., Changning Dist., Shanghai, the PRC on Friday, November 13, 2026 at 2:00 p.m. Unless otherwise defined, capitalized terms in this announcement shall have the same meaning as given to them in the Notice.

The total number of the issued Shares of the Company as at the date of the EGM was 227,071,600 H Shares, among of which, 3,702,400 H Shares were held by the Company as treasury shares and did not carry voting rights. For the avoidance of doubt, holder of treasury shares was not entitled to vote and had abstained from voting on the resolutions proposed at the EGM. Accordingly, the total number of H Shares entitling the holders to attend and vote for or against or abstain from voting any of the proposed resolutions at the EGM was 223,369,200 H Shares.

As at the date of the EGM, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("**Zhongmei Huadong**"), which is wholly-owned by Huadong Medicine Co., Ltd. ("**Huadong Medicine**"), held 35,900,000 H Shares of the Company, representing approximately 16.07% of the issued share capital of the Company (excluding H Shares held by the Company as treasury shares). Huadong Medicine Investment Holding (Hong Kong) Limited ("**Huadong Investment**"), which is wholly-owned by Huadong Medicine, held 1,976,800 H Shares of the Company, representing approximately 0.88% of the issued share capital of the Company (excluding H Shares held by the Company as treasury shares). Accordingly, Zhongmei Huadong and Huadong Investment are required to abstain from voting on the resolution to approve the Revised Annual Caps for the three financial years from 2026 to 2028 as set out in the Circular for the Continuing Connected Transactions under the QX001S Framework Agreement at the EGM. As far as the Directors are aware, having made all reasonable enquiries, save for Zhongmei Huadong and Huadong Investment, no other Shareholders are required to abstain from voting on the resolutions at the EGM. There were no other H Shares entitling the shareholders to attend and abstain from voting in favour of any of the proposed resolutions at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Listing Rules**"). None of the shareholders of the Company has stated his or her intention in the Circular to vote against or abstain from voting on any resolutions at the EGM.

The number of shareholders and proxies of shareholders attending the EGM in person was 3. Shareholders and proxies of shareholders who attended the EGM in respect of resolution numbered 1 held a total of 123,554,200 H Shares with voting rights, representing approximately 66.61% of the total number of H Shares with voting rights. Shareholders and proxies of shareholders who attended the EGM in respect of resolution numbered 2 held a total of 161,431,000 H Shares with voting rights, representing approximately 72.27% of the total number of H Shares with voting rights.

The holding of the EGM was in compliance with the requirements of the Company Law of the PRC (《中華人民共和國公司法》) and the Articles of Association of the Company.

Tricor Investor Services Limited, the Company's H share registrar, acted as the scrutineer for the vote-taking at the EGM.

The following Directors of the Company attended the EGM: Mr. Qiu Jiwan, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors; Mr. Wu Zhiqiang as non-executive Director; and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive Directors.

VOTING RESULTS OF THE EGM

At the EGM of the Company held on November 13, 2026, all the proposed resolutions as set out in the Notice were taken by poll. The poll results are as follows:

Ordinary Resolutions		**Number of Votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and, if thought fit, approve the Revised Annual Caps for the three financial years from 2026 to 2028 as set out in the Circular for the Continuing Connected Transactions under the QX001S Framework Agreement; and to authorize any Director to exercise all powers which they consider necessary and do such other acts and things and execute such other documents which in their opinion may be necessary or desirable to implement the transactions contemplated under the QX001S Framework Agreement.	123,554,200 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and, if thought fit, approve the appointment of Dr. Ji Juan as a non-executive Director of the second session of the Board and the remuneration proposed by the Board.	161,431,000 (100.00%)	0 (0.00%)	0 (0.00%)
As more than half of the votes were cast in favour of all the resolutions above, the resolutions were duly passed as ordinary resolutions.				

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Reference is made to the announcement of the Company dated September 22, 2026 (the "**Announcement**") in relation to the resignation of Mr. Yu Xi as a non-executive Director and the proposed appointment of Dr. Ji Juan ("**Dr. Ji**") as a non-executive Director. The resolution on the appointment of Dr. Ji as a non-executive Director was duly passed by the Shareholders at the EGM and has taken effect from the conclusion of the EGM. The term of Dr. Ji will commence from the date of the EGM and end on the expiry of the second session of the Board. For the biographical details and other information of Dr. Ji, please refer to the Announcement.

CHANGE IN COMPOSITION OF BOARD COMMITTEE

Reference is made to the Announcement. Following the conclusion of the EGM regarding the appointment of Dr. Ji, the Board hereby announces that, the composition of the following Board committee of the Company has been changed as follows with effect from November 13, 2026 and terminates upon the expiry of the second session of the Board:

The composition of the Strategy and Development Committee is changed to: Mr. Qiu Jiwan (Chairman), Dr. Ji Juan and Dr. Zou Zhongmei.

By Order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, November 13, 2026

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Wu Zhiqiang and Dr. Ji Juan as non-executive Directors, and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive Directors.